Survival of colorectal cancer cell lines treated with paclitaxel, radiation, and 5-FU: Effect of TP53 or hMLH1 deficiency

International Journal of Cancer

Volumn 90, Issue 4, 2000, Pages 175-185

  Kennedy, Andrew S ^a   Harrison, George H ^a   Mansfield, Carl M ^a   Zhou, Xiao Juan ^a   Xu, Jing Fan ^a   Balcer Kubiczek, Elizabeth K ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

5 FU; BNIP3; Colon; MYC; Paclitaxel (Taxol); Radiation; Survivin; TP53, hMLH1

Indexed keywords

CELL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; FLUOROURACIL; MESSENGER RNA; PACLITAXEL; PROTEIN MLH1; PROTEIN P53; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; RADIOSENSITIVITY;

NON-PROGRAMMATIC;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARRIER PROTEINS; CELL SURVIVAL; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PACLITAXEL; PROTEINS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033859532     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20000820)90:4<175::AID-IJC1>3.0.CO;2-W     Document Type: Article

References (68)

1. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis
2. Microsatellite instability in cancer of the proximal colon
3. Hypermutability and mismatch repair deficiency in RER+ tumor cells
4. Mutations of a MutS homolog in hereditary non-polyposis colorectal cancer
5. Mutation in mismatch mutation homologue hMLH1 is associated with hereditary non-polyposis colon cancer
6. Mutation of a MutL homolog in hereditary colon cancer
7. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability
8. Mechanisms of inactivation of mismatch repair genes in human colorectal cancer cell lines: The predominant role of hMLH1
9. IARC Database of p53 mutations in human tumors and cell lines: Updated compilation, revised formats and new visualization tools
10. Molecular epidemiology of human cancer: Contribution of mutation spectra studies of tumor suppressor genes
11. APC mutations in colorectal cancers with mismatch repair deficiency
12. Genomic instability and alterations in Apc, Mcc, and Dcc in Hong Kong patients with colorectal carcinoma
13. Somatically acquired genetic alterations in flat colorectal neoplasias
14. Comparison of the genetic pathways involved in the pathogenesis of three types of colorectal cancer
15. Identification of c-MYC as a target of the APC pathway
16. Myc suppresses induction of the growth arrest genes gadd34, gadd45, and gadd153 by DNA damaging agents
17. Tumor microsatellite instability and clinical outcome in young patients colorectal cancer
18. Defects in mismatch repair occur after APC mutations in the pathogenesis of sporadic colorectal tumours
19. Evaluation of the replication error phenotype in relation to molecular and clinicopathological features in hereditary and early onset colorectal cancer
20. Microsatellite instability in sporadic colorectal carcinoma is not an indicator of prognosis
21. Replication error in colorectal carcinoma: Association with loss of heterozygosity at mismatch repair loci and clinico-pathological variables
22. Adjuvant therapy of colorectal cancer
23. Adjuvant therapy in colon cancer
24. Therapy for early-stage colorectal cancer
25. Postoperative radiation therapy for high-risk colon carcinoma
26. A randomized feasibility study evaluating the effect of radiotherapy alone or combined with 5-fluorouracil in the treatment of locally recurrent or inoperative colorectal carcinoma
27. Adjuvant continuous infusion 5-FU, whole-abdominal radiation and tumor bed boost in high-risk stage III colon carcinoma: A Southwest Oncology Group Pilot study
28. Whole abdominal radiotherapy and concomitant 5-fluorouracil as adjuvant therapy for colon cancer
29. Pilot study of continuous-infusion 5-fluorouracil, oral leucovorin, and upper-abdominal radiation therapy in patients with locally advanced residual or recurrent upper gastrointestinal or extrapelvic colon cancer
30. Combined treatment of large bowel
31. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma
32. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer
33. Combination of taxanes with radiation: Preclinical studies
34. Taxanes in combined-modality therapy for solid tumors
35. Apoptosis as a predictor of paclitaxel-induced radiosensitization in human tumor cell lines
36. Radiobiological effects of docetaxel (Taxotere): A potential radiation sensitizer
37. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
38. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro
39. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells
40. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitroguanine tolerance in colon cells with homozygous hMLH1 mutation
41. 2 arrest after DNA damage
42. 2-M cell cycle checkpoint arrest following ionizing radiation
43. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radio-sensitization in human colon cancer cells
44. Disruption of p53 in human cancer cells alters the response to therapeutic agents
45. p53 Mutational status and survival of wild-type and adriamycin-resistant sublines of human breast cancer MCF7 cells to X- or fission neutron-irradiation
46. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
47. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells
48. Delayed expression of hpS2 and prolonged expression of CIP1/WAFI/SDII in human tumour cells irradiated with X-rays, fission neutrons or 1 GeV/n Fe ions
49. Repair of DNA double-strand breaks and radiosensitivity to killing in an isogenic group of p53 mutant cell lines
50. Dependence on Rad52 and Rad51 for anticancer drug resistance mediated by inactivation of mismatch repair genes
51. A novel antiapoptotic gene, survivin, expressed in cancer and lymphoma
52. IAP-family protein Survivin inhibits caspase activity induced by Fas (CD95), Bax, Caspases, and anticancer drugs
53. Control of apoptosis and mitotic spindle checkpoint by survivin
54. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer
55. Analysis of Bcl-2, Bax, and survivin genes in uterine cancer
56. Tumor content of the antiapoptotic molecule survivin and recurrence of bladder cancer
57. BIGEL analysis of gene expression in HL60 cells exposed to X rays or 60-Hz magnetic fields
58. Nix and Nip3 form a subfamily of pro-apoptotic mitochondrial proteins
59. Identification and classification of p53-regulated genes
60. Rodent cell transformation and immediate early gene expression following 60-Hz magnetic field exposure
61. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
62. Pharmacodynamics of immediate and delayed effects of paclitaxel: Role of slow apoptosis and intracellular drag retention
63. Mitotic block induced in HeLa cells by low concentration of paclitaxel (Taxol) results in mitotic exit and apoptotic death
64. Mutations of mitotic checkpoints in human cancers
65. Adenovirus E1B-19KD/BCL-2 interacting protein BNIP3 contains a BH3 domain and a mitochondrial targeting sequence
66. CDX2 is mutated in a colorectal cancer with normal APC/β-catenin signaling
67. Amplification of c-MYC as the origin of the homogeneous staining region in ovarian carcinoma detected by micro-FISH
68. Genetic instability in colorectal cancers